Which organizations jointly acquired the patents for the conversational AI program?

The patents were acquired by FRONTEO Inc. and a group led by Professor Taishiro Kishimoto of Keio University School of Medicine.

What are the registration date and numbers of the acquired patents?

The registration date is January 20, 2026, and the patent numbers are Patent No. 7807764 and Patent No. 7807765.

What are the two perspectives of determination addressed by the patents?

The two perspectives are the patient's 'State' of actually suffering from depression and the patient's 'Trait' or predisposition.

What are the main objectives of developing this conversational AI program?

The objectives are supporting diagnosis by doctors, establishing methods for early detection, and securing objective evidence in diagnosis.

AI News NQ Analysis

FRONTEO and Keio University School of Medicine Acquire Two Patents for Conversational AI Program Supporting Depression Diagnosis

NQ Score 100/100

AI Summary (NQ-processed)

FRONTEO Inc. and Keio University School of Medicine have jointly developed and patented two conversational AI programs designed to assist in the diagnosis of depression. These programs analyze approximately 10 minutes of free conversation between patients and healthcare professionals to provide objective diagnostic support, aiming to improve early detection and treatment access for depression patients.

AI analysis data is not yet available.

Frequently Asked Questions

Q: Which organizations jointly acquired the patents for the conversational AI program?: A: The patents were acquired by FRONTEO Inc. and a group led by Professor Taishiro Kishimoto of Keio University School of Medicine.
Q: What is the primary method used by the conversational AI program to analyze patients?: A: The program analyzes approximately 10 minutes of free conversation between patients and healthcare professionals.
Q: What are the registration date and numbers of the acquired patents?: A: The registration date is January 20, 2026, and the patent numbers are Patent No. 7807764 and Patent No. 7807765.
Q: What are the two perspectives of determination addressed by the patents?: A: The two perspectives are the patient's 'State' of actually suffering from depression and the patient's 'Trait' or predisposition.
Q: What are the main objectives of developing this conversational AI program?: A: The objectives are supporting diagnosis by doctors, establishing methods for early detection, and securing objective evidence in diagnosis.